Last edition
News about "obinutuzumab"
Roche's Gazyva Receives US FDA Priority Review for Membranous Nephropathy
The US Food and Drug Administration (FDA) has granted Priority Review to Roche's Gazyva for primary membranous nephropathy, supported by phase 3 MAJESTY trial results showing superior complete remission versus tacrolimus.
Obinutuzumab | 17/07/2026 | By News Bureau
Genentech's Gazyva Shows Strong Phase III Results in Primary Membranous Nephropathy
Phase III MAJESTY trial shows Gazyva significantly improves complete remission rates in primary membranous nephropathy, potentially paving the way for the first targeted therapy for the condition.
Obinutuzumab | 17/02/2026 | By News Bureau | 164
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy